AFT Pharmaceuticals’ year of two halves
The listed pharma hit record revenue in FY25 after a second-half recovery.
AFT founder and managing director Dr Hartley Atkinson.
A second-half recovery has boosted AFT Pharmaceuticals' full-year result to a record revenue of $208 million for FY25, up 6% on the prior year.
The revenue target has now shifted from $200m to $300m by the end of FY27, which would require a ramp-up in the annual growth rate from recent
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Already have an account? Login
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
